Xylose as a carrier for boron containing compounds

Area of Science:

• Biochemistry
• Cell Biology
• Carbohydrate Chemistry

Background:

• Boron neutron capture therapy (BNCT) is an experimental cancer treatment.
• Carboranes are boron-containing compounds with potential therapeutic applications.
• Xylosides can be functionalized to deliver therapeutic agents to cells.

Purpose of the Study:

• To synthesize and evaluate a xylosylated carborane for potential use in BNCT.
• To assess the compound's effects on glycosaminoglycan (GAG) synthesis and proteoglycan localization in normal and cancer cells.
• To determine the suitability of this compound for BNCT targeting T24 bladder cancer cells.

Main Methods:

• Synthesis of a xylosylated carborane using standard carbohydrate chemistry.
• Treatment of normal HFL-1 cells and transformed T24 cells with the synthesized compound.
• Analysis of GAG synthesis initiation.
• Observation of proteoglycan translocation to the nucleus.
• Quantification of boron-containing compound secretion.

Main Results:

• The xylosylated carborane successfully initiated GAG synthesis in both HFL-1 and T24 cells.
• A significant translocation of proteoglycans to the nuclei of T24 cells was observed upon treatment.
• The majority of the boron-containing carborane compound was secreted into the cell medium.
• The compound showed limited retention within the T24 cells, hindering its potential for BNCT.

Conclusions:

• Xylosides carrying carboranes are not optimal for BNCT targeting T24 cells due to poor retention.
• The compound's ability to prime GAG synthesis and induce nuclear translocation of glypican-1 warrants further investigation for other tumor cell lines.
• Further research is needed to explore the selectivity and efficacy of this boron-containing xyloside against different cancer types.